RainMed Medical

RainMed Medical operates as a vascular interventional surgical robotics company with a strategic focus on building platform-level robotic systems for coronary artery diagnosis and treatment. Listed on the Hong Kong Stock Exchange in July 2022, the company has established itself as a pioneer in computational fluid dynamics-based coronary functional assessment technology.

Company Overview

Founded in 2014 and headquartered in Zhuhai with major R&D and production facilities in Suzhou Industrial Park, RainMed Medical has positioned itself at the intersection of AI algorithms, medical imaging, and robotic surgery. The company’s long-term strategic vision centers on developing an integrated vascular interventional surgical robot platform covering the entire diagnosis-to-treatment workflow.

RainMed went public on the Hong Kong Stock Exchange main board on July 8, 2022 (Stock Code: 2297.HK), representing a Chapter 18A biotech listing. The IPO marked a significant milestone as the company transitioned from R&D-focused operations to broader commercialization of its diagnostic products.

Core Products

FlashAngio caFFR System

The coronary angiography-derived fractional flow reserve (caFFR) system represents RainMed’s flagship commercial product. Using proprietary computational fluid dynamics algorithms, the system calculates FFR values from standard angiographic images without requiring invasive pressure guidewires or hyperemic agents.

The caFFR system received both NMPA approval and CE Mark certification in 2019, becoming one of the first domestic Chinese FFR products to achieve international regulatory clearance. The system has also obtained TGA certification in Australia (2022) and market registration in Serbia and South Africa.

FlashAngio caIMR System

The coronary angiography-derived index of microvascular resistance (caIMR) system addresses coronary microcirculation assessment—a clinical need previously difficult to address without invasive guidewire-based measurements. The system obtained NMPA approval in April 2023 as a Class III medical device.

RainMed positions caIMR as the world’s first commercially approved non-interventional microcirculation diagnostic product. Clinical validation demonstrated 93.81% accuracy in the Flash III pre-market clinical study.

FlashBot Vascular Interventional Surgery Robot

FlashBot represents the company’s integrated platform-level surgical robot system designed to cover the full workflow of vascular interventional procedures. The robot comprises three functional units: surgical image navigation system, console system, and bedside manipulator with instrument control.

The system has completed animal experiments in Suzhou, demonstrating capabilities including automatic optical positioning puncture, angiography-guided catheter advancement, functional diagnosis, and surgical navigation. FlashBot is designed to integrate the caFFR and caIMR diagnostic modules as its “brain” component.

Technology & Innovation

RainMed’s core technical competencies span multiple domains:

• Medical imaging algorithms: Proprietary 3D reconstruction from 2D angiographic images
• Computational fluid dynamics (CFD): Real-time blood flow simulation for functional assessment
• High-performance mechanical design: Robotic manipulator systems for catheter control
• Interventional consumables: Proprietary FlashPressure pressure sensors

The caFFR system achieves FFR calculation in approximately 2-3 minutes with reported consistency of 95.7% compared to guidewire-derived FFR measurements. This non-invasive approach eliminates the need for hyperemic agents and pressure guidewires, reducing procedure time and risk.

Market Presence

The company has built a global R&D, production, sales, and service network with strategic partnerships including:

• SINOMED (688108.SH): Strategic collaboration signed in February 2023
• Angiotec (Tianjin): Strategic cooperation for market expansion

Clinical validation and research collaboration with leading medical centers has resulted in publications in authoritative journals including Cardiovascular Research and JACC: Cardiovascular Interventions.

Revenue growth has been substantial, with the company reporting RMB 6.097 million in 2020 and RMB 81.199 million in 2021, representing a growth rate of 1,231.8%.

Key Milestones

• 2014: Company founded with vascular interventional robot as strategic goal
• 2015: Animal laboratory established; first functional module experiments completed
• 2019: caFFR system receives NMPA approval and CE Mark certification
• 2022: Hong Kong Stock Exchange IPO (July); TGA certification obtained (September)
• 2023: caIMR system receives NMPA approval (April); Serbia market launch

Pipeline Products

Beyond current commercial products, RainMed’s pipeline includes:

• Flash IVL: Intravascular lithotripsy (shock wave balloon) system
• Flash RDN: Renal denervation ablation system

These products align with the company’s strategy to build a broad platform covering heart, brain, lung, kidney, and peripheral vascular interventions.

Frequently Asked Questions

What products does RainMed Medical currently sell?

RainMed commercializes two main diagnostic products: the FlashAngio caFFR System for coronary stenosis assessment and the FlashAngio caIMR System for microcirculation evaluation. Both products are approved by NMPA in China.

Is FlashBot available for clinical use?

FlashBot remains in development phase. The system has completed animal experiments but has not yet received regulatory approval. The company originally targeted 2024 commercialization.

Where is RainMed Medical headquartered?

RainMed Medical is headquartered in Zhuhai with major R&D and production facilities located at Suzhou Industrial Park (Building 31, Northeast District, Nano City).